Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes
Open Access
- 11 February 2021
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (3), 681-689
- https://doi.org/10.2337/dc20-2360
Abstract
OBJECTIVE: The optimal method of monitoring glycemia in pregnant women with type 1 diabetes remains controversial. This study aimed to assess the predictive performance of HbA1c, continuous glucose monitoring (CGM) metrics, and alternative biochemical markers of glycemia to predict obstetric and neonatal outcomes. RESEARCH DESIGN AND METHODS: One hundred fifty-seven women from the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT) were included in this prespecified secondary analysis. HbA1c, CGM data, and alternative biochemical markers (glycated CD59, 1,5-anhydroglucitol, fructosamine, glycated albumin) were compared at ∼12, 24, and 34 weeks’ gestation using logistic regression and receiver operating characteristic (ROC) curves to predict pregnancy complications (preeclampsia, preterm delivery, large for gestational age, neonatal hypoglycemia, admission to neonatal intensive care unit). RESULTS: HbA1c, CGM metrics, and alternative laboratory markers were all significantly associated with obstetric and neonatal outcomes at 24 weeks’ gestation. More outcomes were associated with CGM metrics during the first trimester and with laboratory markers (area under the ROC curve generally 140 mg/dL [>7.8 mmol/L]) were the most consistently predictive CGM metrics. HbA1c was also a consistent predictor of suboptimal pregnancy outcomes. Some alternative laboratory markers showed promise, but overall, they had lower predictive ability than HbA1c. CONCLUSIONS: HbA1c is still an important biomarker for obstetric and neonatal outcomes in type 1 diabetes pregnancy. Alternative biochemical markers of glycemia and other CGM metrics did not substantially increase the prediction of pregnancy outcomes compared with widely available HbA1c and increasingly available CGM metrics (TIR and TAR).Keywords
Funding Information
- Juvenile Diabetes Research Foundation (17-2011-533, 80-2010-585, Sanofi-EFSD Innovative outcomes grant, 2017)
- Diabetes UK (DUK-HKF 17/0005712)
- European Foundation for the Study of Diabetes (EFSD-Novo Nordisk Foundation NNF19SA058974)
- National Institute for Health Research (CDF-2013-06-035)
This publication has 41 references indexed in Scilit:
- 1,5-Anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitusDiabetologia, 2013
- Glycated albumin in diabetic patients with chronic kidney diseaseClinica Chimica Acta; International Journal of Clinical Chemistry, 2012
- Glucose Variability in Diabetic PregnancyDiabetes Technology & Therapeutics, 2011
- Optimal Glycemic Control, Pre-eclampsia, and Gestational Hypertension in Women With Type 1 Diabetes in the Diabetes and Pre-eclampsia Intervention TrialDiabetes Care, 2011
- Nontraditional Markers of GlycemiaDiabetes Care, 2011
- A1C but Not Serum Glycated Albumin Is Elevated Because of Iron Deficiency in Late Pregnancy in Diabetic WomenDiabetes Care, 2009
- Elevated third-trimester haemoglobin A1c predicts preterm delivery in type 1 diabetesJournal of Diabetes and its Complications, 2008
- Blood glycated haemoglobin, serum fructosamine, serum glycated albumin and serum glycated total protein as measures of glycaemia in diabetes mellitusScandinavian Journal of Clinical and Laboratory Investigation, 1992
- Serum fructosamine is not a useful screening test for gestational diabetesEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1991
- FRUCTOSAMINE IN DIABETIC PREGNANCYThe Lancet, 1983